Maps for prep: dissolving microarray patches (maps) for long acting HIV and pregnancy prevention

Ended Cooperative Agreement Awarded Last action

Award ID
AIDOAAA1700015
Recipient
Awarding agency
Obligated
$8,302,779

Award facts

Completion date
Originally
Place of performance
Seattle, WA 98121, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment -$1,140,851
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $1,036,597
Amendment $0
Amendment $2,000,000
Amendment $3,707,918
Amendment The microbicide field is at a critical moment. Two phase III clinical trials of a dapivirine- releasing vaginal ring announced in early 2016 both found a… $0
Amendment Deobligation -$250,000
Amendment $250,000
Amendment $0
Amendment $1,739,029
Original award $960,086
Show all 15

Subawards

Subrecipient Amount Awarded
University Of Bristol In relation to MAPs for PrEP: Dissolving Microarray Patches (MAPs) for long-acting HIV and pregnancy prevention, PATH is engaging University of Bristol to… $93,212
London School Of Hygiene And Tropical Medicine The London School of Hygiene and Tropical Medicine (LSHTM) will work with PATH on a modeling analysis to evaluate the potential uptake and health impact of an… $125,646
Kindeva Drug Delivery LP Specifically, in relation to PATH’s project aimed at advancing development of microarray patches (“MAPs�) as an easy-to-use discreet drug… $999,258
G & L Scientific Inc. In this project, G&L Scientific will compile documentation for and hold a pre-IND meeting with the FDA. $238,426
Genesis Analytics (Pty) LTD Genesis Analytics will collaborate with PATH to assess the usability and acceptability of MAP technology among potential users, providers, and other… $149,242
Makerere University College Of Health Sciences The Child Health and Development Center (CHDC) at Makarere University will collaborate with PATH to assess the usability and acceptability of MAP technology… $147,886
Subrecipient not on record LVCT Health will collaborate with PATH to assess the usability and acceptability of MAP technology among potential users, providers, and other stakeholders in… $76,020
The Queen's University Of Belfast PATH is collaborating with Queens University of Belfast to support the development of cabotegravir and contraceptive microarray patches. $1,955,840
The Population Council, Inc. Preclinical studies and regulatory strategy for contraceptive and cabotegravir MAPs $961,640

Quick answers

Who received award AIDOAAA1700015?

AIDOAAA1700015 was awarded to Path by Bureau for Global Health (Washington Office) on June 27, 2017.

How much is award AIDOAAA1700015 worth?

$8,302,779 has been obligated on AIDOAAA1700015.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login